• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by OptimizeRx Corporation

    8/29/25 2:31:28 PM ET
    $OPRX
    Real Estate
    Real Estate
    Get the next $OPRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001296525
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    OptimizeRx Corp
    SEC File Number
    001-38543
    Address of Issuer
    260 CHARLES STREET
    SUITE 302
    WALTHAM
    MASSACHUSETTS
    02453
    Phone
    248-651-6558
    Name of Person for Whose Account the Securities are To Be Sold
    Spangler Patrick D
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Merrill
    80 South 8th Street
    Suite 4000
    Minneapolis � MN � 55402
    11120198000.001856503308/28/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/31/2019Restricted Stock AwardOptimizeRx CorporationCheckbox not checked208410/01/2019Restricted Stock Vest
    Common06/30/2019Restricted Stock AwardOptimizeRx CorporationCheckbox not checked208412/30/2019Restricted Stock Vest
    Common09/30/2019Restricted Stock AwardOptimizeRx CorporationCheckbox not checked208403/30/2020Restricted Stock Vest
    Common12/31/2019Restricted Stock AwardOptimizeRx CorporationCheckbox not checked208407/01/2020Restricted Stock Vest
    Common03/31/2020Restricted Stock AwardOptimizeRx CorporationCheckbox not checked278410/01/2020Restricted Stock Vest

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    08/29/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    05/27/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Patrick D Spangler

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $OPRX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPRX

    DatePrice TargetRatingAnalyst
    1/8/2025$7.00 → $6.00Outperform → Sector Perform
    RBC Capital Mkts
    12/20/2024$5.50Equal-Weight
    Stephens
    7/25/2024$18.50Buy
    B. Riley Securities
    4/4/2024$15.00Mkt Outperform
    JMP Securities
    1/3/2024$15.00Equal Weight
    Barclays
    2/2/2023$30.00Buy
    B. Riley Securities
    11/1/2022$19.00Buy
    Stifel
    7/15/2022$38.00Outperform
    SVB Leerink
    More analyst ratings

    $OPRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lang James Paul bought $2,443,761 worth of shares (321,408 units at $7.60), increasing direct ownership by 472% to 389,452 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    3/19/25 7:40:24 PM ET
    $OPRX
    Real Estate

    CEO Febbo William J bought $100,220 worth of shares (20,000 units at $5.01), increasing direct ownership by 3% to 601,253 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    12/16/24 2:28:39 PM ET
    $OPRX
    Real Estate

    $OPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    OptimizeRx downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded OptimizeRx from Outperform to Sector Perform and set a new price target of $6.00 from $7.00 previously

    1/8/25 8:17:01 AM ET
    $OPRX
    Real Estate

    Stephens initiated coverage on OptimizeRx with a new price target

    Stephens initiated coverage of OptimizeRx with a rating of Equal-Weight and set a new price target of $5.50

    12/20/24 7:46:38 AM ET
    $OPRX
    Real Estate

    B. Riley Securities resumed coverage on OptimizeRx with a new price target

    B. Riley Securities resumed coverage of OptimizeRx with a rating of Buy and set a new price target of $18.50

    7/25/24 8:24:56 AM ET
    $OPRX
    Real Estate

    $OPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OptimizeRx to Participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference

    WALTHAM, Mass., Sept. 10, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference taking place Thursday, September 11, 2025, in New York, NY. To request a meeting or for more details about the Conference, please reach out to your institutional contact. About OptimizeRx OptimizeRx is a leading healthcare technology company that's redefining how life science brands connect with patients and healthcare prov

    9/10/25 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

    Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (NASDAQ:LAMR), one of the largest out-of-home (OOH) advertising companies in North America, today announced a strategic partnership to revolutionize OOH advertising for pharmaceutical and healthcare brands. Through this collaboration, OptimizeRx's

    9/9/25 4:05:00 PM ET
    $LAMR
    $OPRX
    Real Estate Investment Trusts
    Real Estate

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    $OPRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Silvestro Stephen L was granted 15,625 shares, increasing direct ownership by 9% to 183,887 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    8/25/25 4:32:47 PM ET
    $OPRX
    Real Estate

    Chief Legal & Admin Officer Odence-Ford Marion was granted 15,625 shares, increasing direct ownership by 22% to 85,901 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    8/25/25 4:29:19 PM ET
    $OPRX
    Real Estate

    CFO/COO Stelmakh Edward was granted 15,625 shares, increasing direct ownership by 16% to 110,764 units (SEC Form 4)

    4 - OptimizeRx Corp (0001448431) (Issuer)

    8/25/25 3:21:06 PM ET
    $OPRX
    Real Estate

    $OPRX
    SEC Filings

    View All

    SEC Form 144 filed by OptimizeRx Corporation

    144 - OptimizeRx Corp (0001448431) (Subject)

    8/29/25 2:31:28 PM ET
    $OPRX
    Real Estate

    OptimizeRx Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OptimizeRx Corp (0001448431) (Filer)

    8/19/25 7:44:18 AM ET
    $OPRX
    Real Estate

    SEC Form 10-Q filed by OptimizeRx Corporation

    10-Q - OptimizeRx Corp (0001448431) (Filer)

    8/8/25 4:02:36 PM ET
    $OPRX
    Real Estate

    $OPRX
    Financials

    Live finance-specific insights

    View All

    OptimizeRx Reports Second Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q2 revenue of $29.2 million, increased 55% year-over-yearQ2 gross profit increased 59% year-over-year to $18.6 millionPaid down $4.5 million of principal on outstanding term loan during Q2Increased full year 2025 guidance to a revenue range between $104 million and $108 million and adjusted EBITDA range between $14.5 million and $17.5 million WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended June 30, 2025. Quarterly comparisons are

    8/7/25 4:01:00 PM ET
    $OPRX
    Real Estate

    OptimizeRx Sets Second Quarter 2025 Conference Call for August 7, 2025, at 4:30 p.m. ET

    WALTHAM, Mass., July 17, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Thursday, August 7, 2025, at 4:30 p.m. Eastern Time to discuss its results for the second quarter period ended June 30, 2025. The financial results will be issued in a press release prior to the call. OptimizeRx management will host the call, followed by a question-and-answer period. Details for the conference call can be found below: Date:Thursday, August 7, 2025Time:4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)T

    7/17/25 7:30:00 AM ET
    $OPRX
    Real Estate

    OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

    Q1 revenue of $21.9 million, increasing 11% year-over-yearQ1 gross profit increased 9% year-over-year to $13.3 millionIncreases full year 2025 guidance to a revenue range between $101 million and $106 million and adjusted EBITDA range between $13 million and $15 million WALTHAM, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today reported results for the three months ended March 31, 2025. Quarterly comparisons are to the same year-ago period. Financial Highlights Revenue in the first quarter of 2025

    5/12/25 4:05:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Leadership Updates

    Live Leadership Updates

    View All

    OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising

    Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- OptimizeRx (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, and Lamar Advertising Company (NASDAQ:LAMR), one of the largest out-of-home (OOH) advertising companies in North America, today announced a strategic partnership to revolutionize OOH advertising for pharmaceutical and healthcare brands. Through this collaboration, OptimizeRx's

    9/9/25 4:05:00 PM ET
    $LAMR
    $OPRX
    Real Estate Investment Trusts
    Real Estate

    OptimizeRx Corporation Announces Leadership Team Advancements to Accelerate Strategic Growth

    WALTHAM, Mass., Aug. 19, 2025 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the "Company") (NASDAQ:OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced organizational updates and leadership advancements designed to accelerate the Company's Rule of 40 strategy—balancing sustained growth with increased profitability. These changes reflect the strength of the Company's leadership bench and CEO Steve Silvestro's commitment to aligning talent and structure with OptimizeRx's long-term strategic objectives under his management. "Over the past six months, I have had the opportunity to ev

    8/19/25 7:30:00 AM ET
    $OPRX
    Real Estate

    Paynela Appoints Healthcare Technology Veteran William Febbo to Board of Directors

    Former OptimizeRX CEO Brings Extensive Digital Health and Pharmaceutical Patient Assistance Expertise to AI-Driven Healthcare Financing Company Paynela, a leading healthcare financing company revolutionizing claim processing through artificial intelligence that leverages AI advancements to process thousands of medical claims in under a minute, today announced the appointment of William Febbo to its Board of Directors, effective immediately. Febbo brings over 30 years of experience in healthcare technology, digital health innovation, and pharmaceutical patient assistance programs to the rapidly growing company. From 2016 to 2025, Febbo served as Chief Executive Officer and Director of Op

    7/30/25 12:00:00 PM ET
    $OPRX
    Real Estate

    $OPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    12/6/24 4:26:03 PM ET
    $OPRX
    Real Estate

    SEC Form SC 13G filed by OptimizeRx Corporation

    SC 13G - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 3:18:35 PM ET
    $OPRX
    Real Estate

    Amendment: SEC Form SC 13G/A filed by OptimizeRx Corporation

    SC 13G/A - OptimizeRx Corp (0001448431) (Subject)

    11/14/24 11:25:34 AM ET
    $OPRX
    Real Estate